Scanning Electron Microscopy Visualization of Methicillin-Resistant Staphylococcus aureus After Contact With Gatifloxacin With and Without Preservative

被引:9
作者
Monson, Bryan K. [1 ]
Stringham, Jack [1 ]
Jones, Brandt B. [2 ]
Abdel-Aziz, Salwa [1 ]
Peck, Carolee M. Cutler [1 ]
Olson, Randall J. [1 ]
机构
[1] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT 84132 USA
[2] Univ Utah, Dept Internal Med, Div Infect Dis, Salt Lake City, UT 84132 USA
关键词
BENZALKONIUM CHLORIDE; RABBIT MODEL; BACTERIAL CONJUNCTIVITIS; ANTIBACTERIAL EFFICACY; KERATITIS; FLUOROQUINOLONE; BESIFLOXACIN; MOXIFLOXACIN; 0.3-PERCENT; INFECTIONS;
D O I
10.1089/jop.2009.0108
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To test a visual model by looking at the differences in effect of Zymar (R) (gatifloxacin plus benzalkonium chloride [BAK]) when compared to gatifloxacin and a normal saline (NS) control upon a methicillin and gatifloxacin-resistant Staphylococcus aureus (MRSA) species. Methods: An ocular isolate of gatifloxacin-resistant (minimal inhibitory concentration >2 to 4 mu g/mL) MRSA was grown to confluency. Chambered slides were prepared with bacterial culture smears, and then incubated with either gatifloxacin at the concentrations of 1 and 10 mu g/mL, Zymar (R) containing equivalent concentrations of gatifloxacin, or NS. Bacterial cultures were fixed after 10, 30, and 60 min. Fixed slides were coated in gold sputter for examination. Bacteria were visually evaluated with scanning electron microscopy (SEM) at 50,000x. Blinded review of SEM images compared structural changes and mitotic activity across samples. Results: MRSA exposed to 10 mu g Zymar (R) for 60 min showed significantly greater pleomorphism and cell wall surface changes when compared to gatifloxacin (P < 0.0001) and NS (P = 0.001), and significantly less mitotic activity than NS (P = 0.002). Conclusion: Using SEM, the topical formulation of gatifloxacin 0.3% (Zymar (R)), which contains BAK, had greater antibacterial activity than did gatifloxacin alone in gatifloxacin and methicillin-resistant S. aureus, thereby illustrating potential advantages of the preservative in the commercial formulation. We further show that these effects can be visualized and quantified.
引用
收藏
页码:133 / 136
页数:4
相关论文
共 27 条
[1]  
*ALL INC, 2004, ZYM PACK INS
[2]   Ocular TRUST: Nationwide antimicrobial susceptibility patterns in ocular isolates [J].
Asbell, Penny A. ;
Colby, Kathryn A. ;
Deng, Sophie ;
McDonnell, Peter ;
Meisler, David M. ;
Raizman, Michael B. ;
Sheppard, John D., Jr. ;
Sahm, Daniel F. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2008, 145 (06) :951-958
[3]  
Blomquist Preston Howard, 2006, Trans Am Ophthalmol Soc, V104, P322
[4]   Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and Levofloxacin against methicillin-resistant Staphylococcus aureus [J].
Blondeau, J. M. ;
Borsos, S. ;
Hesje, C. K. .
JOURNAL OF CHEMOTHERAPY, 2007, 19 (02) :146-151
[5]   Update on bacterial conjunctivitis in south Florida [J].
Cavuoto, Kara ;
Zutshi, Deepti ;
Karp, Carol L. ;
Miller, Darlene ;
Feuer, William .
OPHTHALMOLOGY, 2008, 115 (01) :51-56
[6]   Antibacterial activity of anesthetic solutions and preservatives - An in vitro comparative study [J].
Dantas, PEC ;
Uesugui, E ;
Nishiwaki-Dantas, MC ;
Mimica, LJ .
CORNEA, 2000, 19 (03) :353-354
[7]   Topical ophthalmic fourth-generation fluoroquinolones: Appropriate use and cost considerations [J].
Fiscella, Richard G. ;
Lewis, Charles C. ;
Jensen, Michael K. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (19) :2069-2073
[8]   Methicillin-resistant staphylococcus aureus disease in three communities [J].
Fridkin, SK ;
Hageman, JC ;
Morrison, M ;
Sanza, LT ;
Como-Sabetti, K ;
Jernigan, JA ;
Harriman, K ;
Harrison, LH ;
Lynfield, R ;
Farley, MM .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (14) :1436-1444
[9]   The dilution of benzalkonium chloride (BAK) in the tear film [J].
Friedlaender, Mitchell H. ;
Breshears, Daphne ;
Amoozgar, Bahram ;
Sheardown, Heather ;
Senchyna, Michelle .
ADVANCES IN THERAPY, 2006, 23 (06) :835-841
[10]   Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria [J].
Haas, Wolfgang ;
Pillar, Chris M. ;
Zurenko, Gary E. ;
Lee, Jacqueline C. ;
Brunner, Lynne S. ;
Morris, Timothy W. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (08) :3552-3560